Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Puente, A
- Turón, F
- Martínez, J
- Fortea, JI
- Guerra, MH
- Alvarado, E
- Pons, M
- Magaz, M
- Llop, E
- Alvarez-Navascués, C
- Navarrete, AA
- Masnou, H
- Bañares, R
- Casado, M
- Ampuero, J
- Rios, J
- Saavedra, C
- Blasi, A
- Lisman, T
- Figuero, CR
- Huelin, P
- Tellez, L
- Arráez, DM
- Rodriguez, M
- Loste, MTA
- Baiges, A
- Hernandez-Gea, V
- Perelló, C
- Calleja, JL
- Genescà, J
- Villanueva, C
- Gonzalez-Alayón, C
- Albillos, A
- Crespo, J
- Garcia-Pagán, JC
Grupos
Abstract
Background & Aims: Previous studies suggest that anticoagulation may reduce the risk of portal hypertension (PHT)-related complications and improve survival in patients with cirrhosis. This study aimed to evaluate the efficacy and safety of the direct oral anticoagulant rivaroxaban in patients with cirrhosis. Methods: This was a randomized, double-blind, placebo-controlled, multicenter trial involving patients with cirrhosis, PHT, and moderate liver dysfunction (Child-Pugh score 7-10). Participants received either rivaroxaban 10 mg daily or placebo for 24 months. The primary composite endpoint was the development of a PHT-related complication or death/liver transplantation, whichever occurred first. Analyses were conducted using both modified intention-to-treat and per-protocol approaches. Results: A total of 90 patients were enrolled (49 placebo, 41 rivaroxaban). After a median follow-up of 10.1 months, 34 patients reached the primary endpoint: 23 (46.9%) in the placebo group vs. 11 (26.8%) in the rivaroxaban group. The cumulative probability of survival free from the primary endpoint at 1 and 2 years was 54.4% and 43.0% in the placebo group, compared to 78.7% and 67.1% in the rivaroxaban group (log-rank p = 0.058). In a post hoc analysis of patients with Child-Pugh B7 scores (n = 55), rivaroxaban showed a potentially beneficial effect (hazard ratio 0.258; 95% CI 0.074-0.900). In the per-protocol analysis (41 placebo, 37 rivaroxaban), the primary event occurred in 19 patients (46.3%) in the placebo group vs. 9 (24.3%) in the rivaroxaban group (hazard ratio 0.463; 95% CI 0.209-1.024). Non-PHT-related bleeding events were more frequent in the rivaroxaban group (36.6% vs. 14.3%; relative risk 2.56; 95% CI 1.16-5.67). However, there were no significant differences in major bleeding events. Conclusions: In patients with cirrhosis and moderate liver dysfunction, rivaroxaban may improve PHT complication-free survival without significantly increasing the risk of major bleeding. ClinicalTrials.gov: NCT02643212. EudraCT Number: 2014-005523-27. (c) 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Copyright © 2025 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0168-8278, 1600-0641
- Tipo:
- Article
- Páginas:
- 1069-1076
- PubMed:
- 40691992
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 7,351 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
JOURNAL OF HEPATOLOGY ELSEVIER
Citas Recibidas en Web of Science: 20
Documentos
- No hay documentos
Filiaciones
Keywords
- Direct oral anticoagulants; Portal hypertension
Portal de investigación